Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.
作者信息
Crombie Jennifer L, Nastoupil Loretta J, Redd Robert, Tang Kevin, Shouse Geoffrey, Herrera Alex F, Chow Victor A, Shadman Mazyar, Castaneda Puglianini Omar, Saucier Anna, Jacobson Caron A, Armand Philippe, Simmons Gary
机构信息
Dana-Farber Cancer Institute, Boston, MA.
University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood Adv. 2021 Sep 28;5(18):3563-3567. doi: 10.1182/bloodadvances.2021004880.
Abstract
摘要
相似文献
1
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.阿基仑赛注射液在成年原发性纵隔B细胞淋巴瘤患者中的真实世界疗效
Blood Adv. 2021 Sep 28;5(18):3563-3567. doi: 10.1182/bloodadvances.2021004880.
2
Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.用于治疗B细胞淋巴瘤的阿基仑赛注射液（奕凯达）
Med Lett Drugs Ther. 2018 Jul 16;60(1551):e122-e123.
3
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
4
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.阿基仑赛注射液，一种用于侵袭性非霍奇金淋巴瘤的一流嵌合抗原受体T细胞疗法。
Leuk Lymphoma. 2018 Aug;59(8):1785-1796. doi: 10.1080/10428194.2017.1387905. Epub 2017 Oct 23.
5
Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.阿基仑赛注射液用于治疗复发/难治性B细胞非霍奇金淋巴瘤。
Drugs Today (Barc). 2018 Mar;54(3):187-198. doi: 10.1358/dot.2018.54.3.2776625.
6
Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛注射液治疗大B细胞淋巴瘤
N Engl J Med. 2023 Sep 21;389(12):1152-1153. doi: 10.1056/NEJMc2309399.
7
Axicabtagene Ciloleucel in Large B-Cell Lymphoma. Reply.阿基仑赛治疗大B细胞淋巴瘤。回复。
N Engl J Med. 2023 Sep 21;389(12):1152-1153. doi: 10.1056/NEJMc2309399.
8
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.嵌合抗原受体 T 细胞疗法 Axicabtagene Ciloleucel 治疗大 B 细胞淋巴瘤的研发与应用：综述。
JAMA Oncol. 2020 Feb 1;6(2):281-290. doi: 10.1001/jamaoncol.2019.3869.
9
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.接受axi-cabtagene ciloleucel治疗后病情进展的大B细胞淋巴瘤患者的预后
Blood. 2021 Apr 1;137(13):1832-1835. doi: 10.1182/blood.2020006245.
10
Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.阿基仑赛注射液用于完全代谢缓解的复发或难治性大B细胞淋巴瘤患者。
Haematologica. 2023 Apr 1;108(4):1163-1167. doi: 10.3324/haematol.2022.281954.
引用本文的文献
1
Optimally Delivered R-da-EPOCH Versus R-CHOP-21 in Primary Mediastinal Large B-Cell Lymphoma: A Real-Life Comparison in a Single Academic Center.原发性纵隔大B细胞淋巴瘤中最佳给药的R-da-EPOCH方案与R-CHOP-21方案的比较：单一学术中心的真实世界对比
Cancers (Basel). 2025 May 19;17(10):1699. doi: 10.3390/cancers17101699.
2
Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New.原发性纵隔B细胞淋巴瘤与[18F]氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描：我们所了解到的及新进展
Hematol Rep. 2025 Apr 28;17(3):23. doi: 10.3390/hematolrep17030023.
3
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma.用于儿童成熟非霍奇金B细胞淋巴瘤的CD28共刺激CD19嵌合抗原受体T细胞
Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02615-0.
4
Long-Term Outcomes and Management Strategies With DA-R-EPOCH in Primary Mediastinal B-Cell Lymphoma: Insights From a Single-Center Experience.原发性纵隔B细胞淋巴瘤采用DA-R-EPOCH方案的长期疗效及管理策略：来自单中心经验的见解
Hematol Oncol. 2025 May;43(3):e70060. doi: 10.1002/hon.70060.
5
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.4个周期后的中期正电子发射断层扫描（PET）可预测经组织分子学确诊的原发性纵隔B细胞淋巴瘤的预后。
Blood Adv. 2025 May 13;9(9):2232-2246. doi: 10.1182/bloodadvances.2024015577.
6
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.原发性纵隔大B细胞淋巴瘤靶向治疗的当前问题与未来展望
J Clin Med. 2025 Feb 11;14(4):1191. doi: 10.3390/jcm14041191.
7
Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.嵌合抗原受体T细胞疗法治疗侵袭性B细胞非霍奇金淋巴瘤患者后的晚期不良事件
JAMA Netw Open. 2025 Feb 3;8(2):e2461683. doi: 10.1001/jamanetworkopen.2024.61683.
8
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.接受抗CD19嵌合抗原受体T细胞（CAR-T）治疗的复发或难治性原发性纵隔B细胞淋巴瘤患者的结局：CARTHYM研究，一项来自法国国家DESCAR-T注册机构的研究
Hemasphere. 2025 Feb 18;9(2):e70091. doi: 10.1002/hem3.70091. eCollection 2025 Feb.
9
Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.超越化疗：淋巴增殖性疾病治疗的现状与未来展望
Biomedicines. 2024 Apr 29;12(5):977. doi: 10.3390/biomedicines12050977.
10
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.纳武单抗联合维布妥昔单抗，联合或不联合纵隔放疗用于复发/难治性原发性纵隔大B细胞淋巴瘤的治疗
Haematologica. 2024 Sep 1;109(9):3019-3023. doi: 10.3324/haematol.2023.284689.
本文引用的文献
1
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.阿基卡宾赛妥昔单抗在非临床试验环境下的疗效、耐药性和毒性的结果和相关性。
J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15.
2
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.阿基仑赛用于复发或难治性大 B 细胞淋巴瘤的标准治疗：来自美国淋巴瘤嵌合抗原受体 T 细胞治疗联盟的结果。
J Clin Oncol. 2020 Sep 20;38(27):3119-3128. doi: 10.1200/JCO.19.02104. Epub 2020 May 13.
3
Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.PMBL 的基因组分析揭示了对 PD-1 阻断敏感的新驱动因素和机制。
Blood. 2019 Dec 26;134(26):2369-2382. doi: 10.1182/blood.2019002067.
4
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.帕博利珠单抗治疗复发或难治性原发性纵隔大 B 细胞淋巴瘤。
J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14.
5
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性原发性纵隔大 B 细胞淋巴瘤：来自 II 期 CheckMate 436 研究的疗效和安全性。
J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.
6
Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.综合基因组分析确定原发性纵隔大 B 细胞淋巴瘤中的关键致病机制。
Blood. 2019 Sep 5;134(10):802-813. doi: 10.1182/blood.2019001126. Epub 2019 Jul 10.
7
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
8
Chimeric antigen receptor-modified T cells: CD19 and the road beyond.嵌合抗原受体修饰的 T 细胞：CD19 及其他途径。
Blood. 2018 Jun 14;131(24):2621-2629. doi: 10.1182/blood-2018-01-785840. Epub 2018 May 4.
9
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
10
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.程序性细胞死亡1配体2（PD-L2）的表达是原发性纵隔（胸腺）大B细胞淋巴瘤的一个显著特征，且与PDCD1LG2拷贝数增加相关。
Am J Surg Pathol. 2014 Dec;38(12):1715-23. doi: 10.1097/PAS.0000000000000297.
Zotero 插件